Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an intravenous formulation for intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage and to treat certain cerebrovascular disorders in adult patients. It is indicated for adult patients at risk of delayed cerebral ischemia and is administered under specialist supervision in acute care settings.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Nimotop (nimodipine) acts on cerebral vasculature to prevent and treat vasospasm‑related complications.

- Subarachnoid hemorrhage (post‑aneurysmal): reduces incidence of delayed cerebral ischemia by preventing vasospasm. - Cerebral vasospasm: provides sustained vasodilation to maintain cerebral blood flow. - Cerebrovascular disorders: supports neuroprotection in acute ischemic events.

Nimotop may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Flushing: warmth and redness of skin.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure fall requiring intervention. - Cardiac arrhythmia: abnormal heart rhythm. - Hepatotoxicity: elevated liver enzymes. - Allergic reaction: rash, pruritus, or anaphylaxis.

When using Nimotop, clinicians should observe specific safety measures.

- Patient selection: use only in adults with confirmed subarachnoid hemorrhage or cerebrovascular risk. - Monitoring: observe blood pressure and neurological status regularly during infusion. - Concomitant vasodilators: avoid simultaneous use with other potent vasodilators to prevent excessive hypotension. - Liver function: assess hepatic function before initiation and monitor during therapy. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; limited data available. - Store below 25°C: keep in original container, protect from light and moisture.

Nimotop can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Other calcium channel blockers: additive vasodilatory effect may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nimodipine plasma levels, raising toxicity risk. - Nitrates: combined use can lead to profound hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive agents: may enhance blood pressure lowering, requiring dose adjustment. - Diuretics: can potentiate hypotensive effect, monitor electrolytes.